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Abstract
Th17 cells and IL-17A play a role in the development and progression of allergic diseases. We analyzed the IL-17A levels in
sputum supernatants (Ss), nasal wash (NW) and plasma (P) from Healthy Controls (HC) and children with Asthma/Rhinitis.
We tested the expression of IL-17A, RORc(t) and FOXP3 in peripheral blood T-lymphocytes from intermittent and mild-
moderate asthma. The effect of Budesonide and Formoterol was tested ‘‘in vitro’’ on IL-17A, RORc(t) and FOXP3 expression
in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis patients, and on nasal and bronchial epithelial
cells stimulated with NW and Ss from mild-moderate asthma/persistent rhinitis. Further, the effect of 12 weeks of treatment
with Budesonide and Formoterol was tested ‘‘in vivo’’ in T-lymphocytes from mild-moderate asthma/persistent rhinitis
patients. IL-17A was increased in Ss, NW and P from children with mild-moderate asthma compared with intermittent and
HC. In cultured T-lymphocytes IL-17A and RORc(t) expression were higher in mild-moderate asthma/persistent rhinitis than
in mild-moderate asthma/intermittent rhinitis, while FOXP3 was reduced. Budesonide with Formoterol reduced IL-17A and
RORc(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the
IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial
epithelial cells. Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4+IL-17A+T-cells, in naı¨ve children
with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment. Th17 mediated immunity may be involved in the
airway disease of children with allergic asthma and allergic rhinitis. Budesonide with Formoterol might be a useful tool for
its therapeutic control.
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Introduction
Allergic diseases, including rhinitis (AR) and asthma, are
chronic inflammatory disorders with a prevailing Th2 immune
response. The inhalation of allergens leads to hyperreactivity,
recruitment of eosinophils, mast cells, and lymphocytes in the
upper and lower airways triggering the inflammatory cascade and
generating local and systemic inflammatory responses. The
presence of an uncontrolled inflammation in the upper and lower
airways as well as in the systemic circulation may compromise the
control of AR and asthma with a consequent progression of the
diseases [1].
T helper (Th) cells, both Th1 and Th2 cells, play an important
role in the initiation and challenge phases of AR and asthma [2,3].
Recent studies have identified an IL-23-dependent T-cell popu-
lation, a Th-cell lineage distinct from Th1 and Th2 called Th17,
which plays an important role in inflammation and tissue injury.
Th17 cells primarily produce Interleukin-17A (IL-17A) by CD4
and CD8 T-cells of both Th1 and Th2 cytokine profiles that
differentiate in Th17 via the activation of the nuclear receptor
retinoic acid–related orphan receptor ct (RORct). IL-17A is
overexpressed in the lung during acute neutrophilic inflammation
and asthma [4]. A number of recent studies have examined the
effect of IL-17A on IL-8 secretion by airway epithelial cells and
airway smooth muscle cells [5,6]. Furthermore, it was observed
that IL-17A induces epigenetic changes which in turn diminish the
ability of glucocorticosteroids (GC) to inhibit IL-8 production from
human bronchial epithelial cells [7].
A balance between Th17 and regulatory T-cells (Tregs) is
crucial for immune homeostasis. Both an excess in Th17 function,
or increased numbers of Th17, and a defect in Treg function or
reduced numbers of Treg, may trigger the development and
progression of inflammatory diseases, including allergic asthma
and rhinitis. Tregs dominantly express Forkhead family transcrip-
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tion factor Foxp3 which activates many suppressive genes in Tregs
and inhibits many effector T cell genes. Pharmacological
treatment might restore the balance between Th17 and Treg
promoting the resolution of inflammation in airway diseases [8]. In
this context, the impact of current pharmacological interventions
is worth to be investigated to counteract the mechanism of
crosstalk between innate and adaptive immunity associated with
Th17 immunity and IL-17A activity during the allergic process.
To better understand the role of IL-17A in asthma and rhinitis
we investigated: 1) the levels of IL-17A in sputum supernatants
(Ss), in nasal wash (NW) and in plasma (P), and 2) the levels of
intracellular IL-17A, RORc(t) and FoxP3 expression in peripheral
T-lymphocytes. Furthermore, we performed in vitro experiments to
test whether the IL-17A present in induced sputum (Ss) and in NW
may compromise the release of IL-8 from bronchial and nasal
airway epithelial cells, and whether the intracellular IL-17A
expressed in T-cells from children with asthma and AR is involved
in the Th17/Treg balance. Finally, we tested the effect of Inhaled
Corticosteroids (ICS) and long-actingb2agonists (LABA) in both
an in vitro and in vivo approach in order to provide new
therapeutic strategies to control the inflammation associated with
Th17 producing IL-17A in children with AR and concomitant
asthma.
Materials and Methods
Subjects
Pediatric subjects (age between 8 and 17 years) were recruited
among outpatients attending the Pulmonology/Allergy Clinic of
the Italian National Research Council in Palermo. Asthma
diagnosis and assessment of severity were performed according
to Global Initiative for Asthma (GINA) guidelines [9]. AR
diagnosis was performed at the study entry according to Allergic
Rhinitis and its Impact on Asthma (ARIA) guidelines [10]. The
patients were divided in two groups: 15 children had intermittent
asthma (IA) (treated with short-acting b2-agonists on demand
during the previous 3 months) and 19 had mild to moderate
asthma (MA). Eight IA patients and 9 MA patients had
concomitant intermittent allergic rhinitis (IR); 7 IA patients and
10 MA patients had concomitant persistent allergic rhinitis (PR).
The control group was composed of 16 healthy children (HC),
tested for allergy to exclude the allergic disease. No patients had
nasal polyposis or bronchial or respiratory tract infections or had a
severe exacerbation of asthma resulting in hospitalization during
the last month. Within 2 days from the collection of Ss, NW, and
blood samples, all subjects performed pulmonary function tests as
recommended by the GINA guidelines [9].
To assess in vivo the effect of the treatment with inhaled GC and
LABA (Budesonide and Formoterol), 10 atopic steroid naı¨ve
patients with MA/PR were studied before and after 12 weeks of
treatment (twice daily 160 mcg/4.5 mcg). The study was ap-
proved by the Ethics Committee of the Policlinic hospital of
Palermo University and complied with the Helsinki Declaration.
Written informed consent was obtained from the parents of the
patients enrolled in the study.
Atopy assessment
All subjects included in the study were assessed for the atopic
status by clinical history and confirmed by skin prick testing (SPT)
(Stallergenes, France) performed by the use of standard prick
method as previously described [11]. House dust mite (Dermatoph-
agoides pteronyssinus and Dermatophagoides farinae) monosensitized
patients were included in the study to select a population as much
homogeneous as possible and to avoid a bias caused by other
additional allergen exposure. Control group had negative SPT and
no asthma or rhinitis symptoms.
Sputum induction and processing
Sputum induction and processing was performed according to
the methods of the plugs as previously described [12].
Nasal Wash fluid collection and processing
NW fluid collection was performed by the Nebuliser connected
with a disposable metered-dose nasal inhaler (Rinowash Markos –
Mefar S.p.A. Bovezzo, BS, Italy). The device consisted of a plastic
cup with a central compartment filled with normal saline solution
(0.9% wt/vol NaCl) at 37uC, and an external compartment
collecting the fluid. Total input of saline solution was 6 ml (3 ml
for each nostril). The subjects were instructed to actively breathe
during a Valsalva maneuver to harvest NW in the cup. Obtained
samples were transferred into conical polypropylene tubes and
processed as previously described by Pizzichini et al. [13] with
minor modifications [14]. Briefly, dithiothreitol (DTT) (Sputolysin,
Calbiochem Corp., San Diego, CA, USA), freshly prepared in a
10% dilution with distilled water, was added to the recovered NW
fluid in the equivalent volume of 1/10th. After homogenization
and centrifugation at 500 g for 10 min at ,4uC, supernatant was
stored at 280uC for later assay and cell pellet was used to prepare
two cytospin slides for total cell counts. Cytocentrifuged slides were
stained with May-Grunwald-Giemsa stain (Sigma Chemical Co.,
St. Louis. MO, USA) and examined by light microscope. The
percentage of the recovered NW versus introduced volume was
58.3%618.6 (mean 6 SD).
Blood sample collection and PBMC culture and
stimulation
Blood samples from patients were collected in EDTA vacutainer
tubes (Becton Dickinson, Mountain View, CA, USA) and used for
plasma selection and PBMC isolation. The cells were isolated by
density gradient centrifugation using gradient intensity (Ficoll-
paqueTM PLUS; Amersham Biosciences SE-751 84, Uppsala,
Sweden) and, after two washes, the cells were suspended in RPMI
1640 cell culture medium (Invitrogen Life Technologies, Italy)
supplemented with 10% heat-inactivated FBS, 2 mM L-gluta-
mine, 20 mM HEPES, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 5610–5 M 2-ME and 85 mg/ml gentamicin. Purity and
viability were tested using trypan blue exclusion. The cells
(16106 cells/ml) were cultured for 72 hours in 24-well cell culture
plates in complete medium in presence or absence of PMA
(50 ng/ml) (Sigma Aldrich, Italy) and ionomycin calcium salt
(250 ng/ml) (Sigma Aldrich, Italy). After the selection of the dose,
Budesonide 1028 M and Formoterol 1028 M (Italchimici S.p.A.-
Italy) combination, were evaluated in the experimental conditions.
The cell viability was evaluated by trypan blu exclusion at the end
of each experiments, to exclude the toxicity of the drugs. The cells
recovered from 10 atopic steroid naı¨ve patients with MA/PR,
studied before and after 12 weeks of treatment, were analyzed
after the PBMC isolation. The cells were processed for intracel-
lular cytokine expression and signal transduction as described
forward.
Intracellular staining of IL-17A cytokine
For the detection of intracellular IL-17A cytokine, PBMC were
cultured overnight in the presence of Golgi Stop (2 mM final
concentration) (Becton Dickinson, Mountain View, CA, USA).
The cells were harvested and put into polypropylene tubes and
then stained with anti-CD3 PE-Cy5 (Becton Dickinson, Mountain
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View, CA, USA) alone or with anti-CD4 FITC (Becton Dickinson,
Mountain View, CA, USA) in incubation buffer (PBS containing
1% FBS and 0.1% Na azide) for 30 min at 4uC. Cells were then
washed twice in PBS with 1% FBS and fixed with PBS containing
4% paraformaldehyde for 20 min at room temperature. Fixed
cells were washed twice in permeabilization buffer (PBS containing
1% FBS, 0.3% saponin, and 0.1% Na azide) for 15 min at 4uC,
and stained with PE anti-human IL-17A (Becton Dickinson,
Mountain View, CA, USA). After two washings in PBS containing
1% FBS, the cells were analyzed by FACSCalibur supported with
CellQuest acquisition and data analysis software (Becton Dick-
inson, Mountain View, CA, USA). Lymphocytes were gated by
forward and side scatter and analysis was done on 100,000
acquired events for each sample.
Intracellular staining of FoxP3 and RORc(t)
PBMC were harvested and washed twice in PBS (containing 1%
FBS and 0.02% Na azide). Suspended cells were stained with
FITC-, PE- or PE-Cy5-conjugated antibodies against CD3, CD4
and CD25 (Becton Dickinson, Mountain View, CA, USA). Cells
were fixed and permeabilized using the human FoxP3 Buffer Set
(Becton Dickinson, Mountain View, CA, USA) following the
manufacturer’s recommended assay procedures. Finally, the cells
were stained with FITC anti-human FoxP3 clone 259D/C7
(Becton Dickinson, Mountain View, CA, USA). For RORc(t)
intracellular staining, suspended cells were stained with anti-CD3
PE-Cy5 (Becton Dickinson, Mountain View, CA, USA), and fixed
and permeabilized as described for FoxP3 intracellular staining.
Finally cells were stained with PE anti-mouse/human RORc(t)
clone AFKJS-9 (eBioscience Inc, San Diego, CA, USA).
Cells (105) from each sample were analyzed using a FACSCa-
libur as described above. Lymphocytes were gated by forward and
side scatter and analysis was done on 100,000 acquired events for
each sample.
Epithelial cell line culture
16-HBE (a differentiated SV-40 transformed bronchial epithe-
lial cell) and human RPMI-2650 (squamous cell carcinoma of the
nasal septum) (American Type Culture Collection, ATCC,
Manassas, VA, USA) cell lines represent a valid in vitro model to
evaluate the functional properties of bronchial and nasal epithelial
cells in inflammation and repair processes [15,16]. Cell lines were
grown in uncoated vented tissue culture flasks (Sarstedt,
Numbrecht, Germany) and incubated at 37uC in a humidified
5% CO2 atmosphere. Cells were maintained in MEM (Gibco)
supplemented with 10% foetal bovine serum (FBS) (Hyclone),
2mM glutamine (Euroclone), Hepes (Euroclone), gentamicin
250 mg/ml (Gibco) and 1% MEM non essential aminoacids
(Gibco). The RPMI-2650 cell line was also supplemented with
sodium piruvate (Lonza, Walkersville, MD, USA).
Stimulation of epithelial cells with Ss and NW
The epithelial cells were grown as mentioned above. After
24 hrs, 16-HBE cells were coincubated with Ss from MA/PR,
while RPMI-2650 cells were coincubated with NW from MA/PR,
in the presence or absence of Formoterol (1028 M) and
Budesonide (1028 M) alone or in combination, or in the presence
or absence of anti IL-17R monoclonal antibody (4 mg/ml, R&D
Systems, Minneapolis, MN, USA) to neutralize human IL-17R
mediated bioactivity. We selected the anti-IL-17R antibody for its
high ability to neutralize the biological activity of IL-17A. After
24 hrs of stimulation, cell supernatants were carefully aspirated,
collected and centrifuged to remove any cell. The cell-free media
were stored at 220uC for IL-8 measurements.
Epithelial cells stimulation with exogenous IL-17A
The 16-HBE (1.06105 cells/ml) or RPMI-2650 (1.56105 cells/
ml) cells were seeded in 1 mL of culture medium in 12-well cell
culture plates (Falcon, Beckton Dickinson) and grown in MEM
10% FBS until 80–90% of confluence. The medium was removed
and replaced with MEM supplemented with 1% FBS. After
24 hrs, the cells were stimulated in the presence or absence of
rhIL-17A (50 ng/ml, R&D Systems, Minneapolis, MN, USA), in
the presence or absence of Formoterol (1028 M) and Budesonide
(1028 M) alone or in combination, or in the presence or absence of
anti IL-17R monoclonal antibody (4 mg/ml, R&D Systems,
Minneapolis, MN, USA) to neutralize human IL-17R mediated
bioactivity.
Measurements of IL-17A and IL-8 by ELISA
The levels of IL-17A were measured in Ss, NW and plasma
from children with MA and IA, and in HC, using a commercial
available enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems. Inc, MN, USA). The lower limit of detection was 15 pg/
ml. IL-8 release was determined in supernatants from cultured
RPMI2650 and 16-HBE cells using a commercial ELISA kit
(Invitrogen Corporation 542 Flynn Rd, Camarillo, CA), according
to the manufactures’ specifications. The lower detection limit was
,5 pg/ml.
Statistical Analysis
Statistical analysis was performed using Kruskal Wallis test and
the differences between groups were evaluated by nonparametric
Mann Whitney test. The results of in vitro experiments were
analyzed using ANOVA with Fisher test correction for multiple
comparisons. Statistical analysis of the data obtained in the
samples before and after treatment in vivo was performed using the
Wilcoxon test. Data were expressed as mean 6 standard deviation
(S.D.) A p value ,0.05 was considered statistically significant.
Results
Demographic characteristics of the patients and cell
count from Ss and NW samples
We reported the demographic characteristics of all patients
included in the study in Table 1. The total and differential cell
count of sputum and NW are reported in Table 2.
Increased levels of IL-17A in allergic children
All the subjects included in the study underwent for plasma,
sputum and nasal wash samples except for three HC that did not
produced sputum. IL-17A levels were significantly increased in Ss
from children with MA when compared to HC (Figure 1A), and in
NW from children with MA compared with HC (Figure 1B). The
IL-17A plasma levels were significantly increased in children with
MA and IA compared with HC. No significant differences were
observed between MA and IA (Figure 1C). Furthermore, we found
that IL-17A levels were significantly increased in Ss and plasma
from MA/PR when compared to MA/IA (Figure 1 D, F). IL-17A
levels in NW were not significantly increased in MA/PR
compared to MA/IR.
Intracellular IL-17A, RORc(t) and FOXP3 expression in T-
cells
We evaluated the percentage of T-cells expressing the
intracellular markers IL-17A, RORc(t) and FOXP3 in asthmatic
patients since we found increased plasma IL-17A in MA and IA.
We found a significant increase of intracellular CD3+IL-17A+
Th17 Immunity in Asthma and Rhinitis of Children
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together with a statistically lower levels of CD3+FOXP3+ in MA
when compared to IA, furthermore we observed higher levels of
intracellular CD3+ RORc(t)+ in this children although without a
statistical significant differences (Figure 2 A, B). Finally, we
observed increased intracellular levels of IL-17A and RORc(t),
and lower intracellular levels of FOXP3 in T-cells from children
with MA/PR when compared to MA/IR (Figure 2C, D).
Effect of the Budesonide and Formoterol on T-cells
Budesonide and Formoterol alone did not affect the intracellular
levels of IL-17A, RORc(t), and FoxP3 expression in cultured T-
cells from children with MA/PR when compared to baseline.
Interestingly, the combined use of both Budesonide and For-
moterol significantly reduced the intracellular levels of IL-17A and
RORc(t) and increased the intracellular levels of Foxp3 in T-cells
from MA/PR when compared to baseline (Figure 3). Finally, since
in asthma the Foxp3 expression is specifically associated with
CD4+CD25+ T-cells, we investigated the Foxp3 expression in T-
cells with this specific phenotype. Interestingly, the combined use
of both Budesonide with Formoterol significantly reduced the
intracellular levels of IL-17A in CD4+T-cells, while increased
intracellular FOXP3 in CD4+CD25+T-cells, when compared to
baseline (Figure 4).
Effect of Budesonide and Formoterol on bronchial and
nasal epithelial cells
We next investigated the effect of IL-17A present in the Ss and
NW from children with MA/PR on bronchial (16-HBE) and nasal
(RPMI2650) epithelial cells activation. 16-HBE and RPMI2650
cells stimulated with Ss and NW from children with MA/PR
significantly increased the release of IL-8 when compared to
baseline. The preincubation of both bronchial and nasal epithelial
cells with Budesonide or Formoterol before the stimulation with Ss
and NW significantly reduced the IL-8 release; the combined
drugs had a stronger synergistic effect on the reduction of IL-8
release by 16-HBE and RPMI2650 cells (Figure 5A, B).
Furthermore, the neutralization of IL-17R by a specific antibody
significantly reduced the Ss and NW-mediated IL-8 release from
both bronchial and nasal epithelial cells (Figure 5C, D). The
stimulation of 16-HBE and RPMI2650 cells with rhIL-17A
showed increased levels of IL-8 release; the preincubation of the
cells with Budesonide or Formoterol reduced the IL-8 production,
while the combined use of both drugs had a stronger additive
effect reducing the release of IL-8 mediated by rhIL-17A (Figure 6
Table 1. Demographic characteristics of patients.
Control Asthma (GINA)
Overall p
value*
Intermittent Mild – Moderate
ARIAu Classes, (n)
Intermittent rhinitis (Mild, Moderate/Severe) 16,00 8,00 9,00
Persistent rhinitis (Mild, Moderate/Severe) 7,00 10,00
Age, (years) 12.1 (61.7) 13.9 (63.3) 13.2 (64.0) ns
Range 8–15 6–17 6–17
Sex, n (Male/Female) 16 (9/7) 15 (8/7) 19 (11/8) ns
Body mass index, (kg/m2) 12.7 (61.1) 14.0 (62.3) 14.4 (62.1) ns
Range 11.2–14.8 10.6–20.3 10.6–18.7
FEV1 (% predicted) 110.0 (69.0) 96.3 (611.0) 86.5 (614.8) ,0.0001
FVC (% predicted) 95.5 (619) 96.0 (610.7) 89.2 (610.4) ,0.0001
FEV1/FVC (ratio %) 89.0 (67.0) 86.2 (67.6) 82.1 (68.6) ns
PEF (% predicted) 80.6 (614.6) 79.7 (618.6) 60.1 (615.7) ,0.0001
SPT, any positive, n (%) 0 100 100 ,0.0001
Total IgE IU/ml, (Geometric mean) 71,94 299,80 632,72 ,0.0001
log tot IgE 1.86 (60.20) 2.48 (60.37) 2.80 (60.29) ,0.0001
doi:10.1371/journal.pone.0058892.t001
Table 2. Total and differential cell count from induced
sputum and nasal lavage.
Controls IA MA
Induced sputum cells
Total cell counts (106
cells/ml)
0.8 (60.7) 1.5 (60.8) 1.2 (60.8)
Squamous cells (%) 3.2 (62.1) 2.7 (62.1) 2 (60.2)
Macrophages (%) 91 (611.2) 56.5 (622.3) 52.5 (623.1)
Eosinophils (%) 0.3 (60.2) 5.8 (62.1) 4 (63.8)
Neutrophils (%) 9 (65.3) 33.5 (62.3) 40 (616.8)
Lymphocytes (%) 0 (60.2) 3.5 (60.2) 2.5 (62.5)
Epithelial cells (%) 0 (61.6) 0.5 (60.3) 1 (61.1)
Nasal lavage cells
Total cell counts (106
cells/ml)
0.01 (60.1) 0.5 (65.3) 0.7 (60.2)
Macrophages (%) 17.1 (614.3) 15.1 (63.3) 14.3 (65.3)
Eosinophils (%) 13.3 (63.3) 22.1 (65.3) 33.3 (67.1)
Neutrophils (%) 23.8 (615.9) 32 (66.3) 32 (66.3)
Epithelial cells (%) 34.4 (632.3) 16.4 (612.3) 8.8 (612.3)
doi:10.1371/journal.pone.0058892.t002
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A, B). Finally, the pretreatment of 16-HBE and RPMI2650 cells
with the anti IL-17R monoclonal antibody significantly reduced
the release of IL-8 generated by rhIL-17A stimulation (Figure 6 C,
D).
Effect of 12 weeks treatment with inhaled Budesonide
and Formoterol
To confirm in vivo the effects of the two drugs on the IL-17A
release shown in the previous ex vivo and in vitro experiments, we
Figure 1. Levels of IL-17A in Control subjects (HC) and patients with asthma and rhinitis. A, B, C) IL-17A levels in Ss, NW and plasma from
HC, IA, and MA groups. Results are expressed as pg/g sputum for Ss, and as pg/ml for NW and plasma. Data are shown as individual values. Statistical
analysis was performed by Kruskal Wallis and Mann-Whitney tests. D, E, F) IL-17A levels in Ss, NW and plasma from MA/IR in comparison with children
with MA/PR. Bars show mean 6 S.D. Statistical analysis was performed by Mann-Whitney test. Significance was accepted at p,0.05.
doi:10.1371/journal.pone.0058892.g001
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Figure 2. T-lymphocytes expressing intracellular IL-17A, RORc(t) and Foxp3 in allergic children. A) Expression of CD3+IL-17A+,
CD3+RORc(t)+ and CD3+Foxp3+ in T-cells from children with IA (n = 15) and MA (n = 19); B) a representative flow cytometry of the data; C) Expression
of CD3+IL-17A+, CD3+RORc(t)+ and CD3+Foxp3+ in T-cells from children with MA/IR (n = 9) in comparison with MA/PR (n = 10); D) a representative flow
cytometry of the data. T-cells (16106 cells/ml) were cultured for 72 hours in 24-well cell culture plates in complete medium in presence of PMA
(50 ng/ml) and ionomycin calcium salt (250 ng/ml). The analysis was performed by flow cytometry. Gates were set on CD3+cells. The bars represent
mean+SD of the % of CD3+ expressing cells. Statistical analysis was performed by Mann-Whitney test. Significance was at p ,0.05.
doi:10.1371/journal.pone.0058892.g002
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Figure 3. Effects of budesonide and formoterol on T-lymphocytes from children with MA/PR (n=10). A) Expression of CD3+IL-17A+; C)
Expression of CD3+RORc(t)+; E) Expression of CD3+Foxp3+;B, D, F) representative flow cytometry of the data. The cells (16106 cells/ml) were cultured
for 72 hours in 24-well cell culture plates in complete medium in presence of PMA (50 ng/ml) and ionomycin calcium salt (250 ng/ml), and then the
effect of Budesonide 1028 M and Formoterol 1028 M alone or in combination was evaluated. The analysis was performed by flow cytometry. Gates
were set on CD3+cells. The bars represent mean+SD of the % of CD3+ expressing cells. Statistical analysis was performed by ANOVA with Fisher test
correction. Significance was at p ,0.05.
doi:10.1371/journal.pone.0058892.g003
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tested the plasma and Ss levels of IL-17A, the percentage of
CD4+IL-17A+ T-cells, in 10 patients with MA/PR at baseline and
after a 12 weeks treatment with inhaled Budesonide and
Formoterol, as described in Materials and Methods. As expected,
the plasma levels of IL-17A (Figure 7A), the % of CD4+IL-17A+
T-cells (Figure 7B), and the Ss levels of IL-17A (Figure 7C) were
significantly reduced after the 12 weeks treatment in comparison
to the baseline. Finally, the % of CD4+CD25+FOXP3+T-cells
showed and increased after 12 weeks of treatment in comaparison
to, although without a statistical differences (data not shown).
Figure 4. Effect of budesonide and formoterol on T-lymphocytes from children with MA/PR (n =10). CD4+IL-17A+ and
CD4+CD25+Foxp3+ T-cells in children with MA/PR (n=10). A) Expression of CD4+IL-17A+; B) a representative flow cytometric detection of
CD4+ T-cell cytokine expression in PBMC. C) Expression of CD4+CD25+Foxp3+; D) a representative flow cytometry analysis of CD4+CD25+ T-cells. PBMC
(16106 cells/ml) were cultured for 72 hours in 24-well cell culture plates in complete medium in presence of PMA (50 ng/ml) and ionomycin calcium
salt (250 ng/ml), in the presence or absence of Budesonide 1028 M and Formoterol 1028 M alone or in combination. The analysis was performed by
flow cytometry. Gates were set on CD3+cells followed by CD4+cells and CD4+CD25+cells. Statistical analysis was performed by ANOVA with Fisher test
correction. Significance was at p,0.05.
doi:10.1371/journal.pone.0058892.g004
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Discussion
This study shows for the first time that increased levels of IL-
17A are involved in the systemic and upper and lower airway
inflammation in children with allergic asthma and rhinitis.
Furthermore, showing higher levels of intracellular IL-17A and
RORc(t), associated with lower levels of Foxp3 in T-lymphocytes,
together with higher plasma levels of IL-17A we suggests that there
is a Th17/Treg imbalance toward Th17 cells in moderate forms of
allergic asthma and rhinitis. In particular we underline that in
these patients the Th17 immunity, responsible of the local
inflammation in the nose and bronchi by the higher levels of IL-
17A present in NW and Ss, is able to increased the production of
IL-8 in nasal and bronchial epithelial cells (Figure 8). Finally this
study provides informations on ICS and LABA as useful
therapeutic strategies to control the Th17 immunity and IL-17A
activity in children with moderate forms of asthma and rhinitis.
In asthma, airway inflammation is characterized by activation
of T helper type-2 (Th-2) T cells, IgE production and eosinophilia.
Uncommitted (naive) CD4+ T helper cells can be induced to
differentiate in specific lineages of T helper type 1 (Th1), Th2,
Th17 and regulatory T cell (Treg) phenotypes in a mutually
Figure 5. Ss and NW from children with MA/PR (n=6) induced the IL-8 release from epithelial cells. 16-HBE and RPMI2650 cells were
stimulated in the presence or absence of Budesonide 1028 M and Formoterol 1028 M alone or in combination A) with Ss (n = 6) or B) with NW from
children with MA/PR; 16-HBE and RPMI2650 cells were stimulated in the presence or absence of anti IL-17R monoclonal antibody C) with Ss or D) with
NW from children with MA/PR. Results are expressed as pg/ml. Data are shown as mean 6 S.D. ANOVA with Fisher test correction was used to
compare the different experimental conditions. **p,0.001 vs baseline; *p,0.001 vs IS; #p,0.05 vs IS. **p,0.001 vs baseline; ##p,0.01 vs NW;
#p,0.05 vs NW.
doi:10.1371/journal.pone.0058892.g005
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exclusive manner. The phenotype of the Treg is defined as being
positive for CD3, CD4, CD25 and also FoxP3, a transcription
factor which is closely related to the suppressive function of Treg
[17,18]. An imbalance between Th1 and Th2 cells occurs in
asthma with an increase of Th2 and a decrease of Th1 cells often
due to a decrease in amount or function of Treg cells [19].
Pathogens or inflammatory mediators may impair the suppressive
function of Tregs in pediatric asthma [20]. Furthermore a number
of groups have recently described the conversion of Tregs into the
Th17 phenotype by the activation of the nuclear receptor retinoic
acid – related orphan receptor ct (RORct) and induced by
appropriate inflammatory stimuli [17,18]. The Th17 cells produce
IL-17A, a cytokine that induces the production of chemokines and
antimicrobial peptides by tissue cells, leading to the recruitment of
neutrophils and inflammation [4].
We demonstrate here that IL-17A is involved in systemic
inflammation of children with MA rather than in children with IA
and HC, accordingly to the increased levels of Th17 and RORc(t)
expression in peripheral T-lymphocytes. Furthermore, when we
considered the MA group, we observed that children with PR
showed higher levels of IL-17A in plasma, higher Th17 and
RORc(t) expression in peripheral T lymphocytes than children
with IR. These findings suggest a role of Th17 immunity and the
related released cytokines in children with the moderate forms of
Figure 6. rhIL-17A induced IL-8 release from epithelial cells. 16HBE cells were stimulated with A) rhIL-17A in the presence or absence of
Budesonide 1028 M and Formoterol 1028 M alone or in combination and B) with rhIL-17A in the presence or absence of anti IL-17R monoclonal
antibody. RPMI2650 cells were stimulated with C) rhIL-17A in the presence or absence of Budesonide 1028 M and Formoterol 1028 M alone or in
combination, and D) with rhIL-17A in the presence or absence of anti IL-17R monoclonal antibody. Results are expressed as pg/ml. Data are shown as
mean6 S.D. of six separate experiments. ANOVA with Fisher test correction was used to compare the different experimental conditions. uup,0.001 vs
baseline; up,0.01 vs rhIL-17A. ###p,0.001 vs rhIL-17A.
doi:10.1371/journal.pone.0058892.g006
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asthma and rhinitis. Finally, the analysis of FOXP3+ T-cells
showed lower levels in children with MA than children with IA: in
particular among MA lower levels of FOXP3+ T-cells were
observed in children with MA/PR than children with MA/IR. All
together these results support the concept that, since circulating
Th17 significantly increased and Treg originally decreased in
children with MA and PR, the Th17/Treg balance is impaired in
these patients and may potentially play a role in the pathogenetic
mechanisms as well as in the progression of allergic diseases.
IL-17 cytokines promote tissue inflammation via the induction
of other pro-inflammatory cytokines and chemokines and, in
humans, several studies have demonstrated that Th17 immunity is
involved in the pathogenesis of allergic diseases [21] with a
potential role in the severity of the disease [22,23]. We show here
higher levels of IL-17A in Ss from children with MA/PR than in
children with MA/IR, contributing to further underline a
potential role of IL-17A in the local airway inflammation of
allergic children, and suggesting that the Th17 mediated immunity
is stronger involved in children with more severe form of allergic
disease. Additionally, since together with differences of Ss we did
not find differences between the levels of IL-17A in NW of
children with MA/PR and MA/IR, our findings support the
concept that the higher levels of IL-17A in the bronchial airways,
in the presence of comorbidity, might be cause of the progression
of asthma disease. On the other hand, IL-17A is a proinflamma-
tory cytokine playing a very important role in the induction and
propagation of inflammation in asthma [24].
The activity of IL-17A is mediated by IL-17 receptor (IL-17R)
expressed by both blood cells and structural cells including T-cells
and the airway epithelial cells [25]. In this scenario, IL-17A in
allergic rhinitis and asthma may cover both the innate and the
adaptive aspects representing the crucial crosstalk between
immune system and structural cells such as airway epithelial cells
and fibroblasts [26,27]. Several in vitro studies have shown that
recombinant IL-17A is able to induce IL-6, IL-8, granulocyte
colony-stimulating factor (GCS-F), nitric oxide (NO) and prosta-
glandin E2 (PGE2) in airway epithelial cells [6]. Accordingly, in
our in vitro model we clearly identified that the stimulation with
rhIL-17A promotes the release of IL-8 in both nasal and bronchial
epithelial cells suggesting that IL-17A might cause the IL-8
mediated airway inflammation in the allergic disease of the nose
and of the bronchi. This observation is further supported by the
IL-8 released from RPMI2650 and 16HBE cells stimulated
respectively with NW and Ss from children with MA/PR that
was abrogated by the preincubation with an anti-IL-17AR MoAb.
Finally, we observed that Ss or NW can induce a stronger release
of IL-8 than rhIL-17A (ng/ml), although the levels of IL-17A in
the Ss are much lower than hrIL-17A used in the experimental
conditions. The explanation might be associated with the presence
of proinflammatory agents in the Ss or NW that alone or
synergistically with IL-17A are involved in the production of IL-8
in airway epithelial cells.
It has been demonstrated that Th17 cells producing IL-17A are
able to induce neutrophilic airway inflammation in mice and that
this inflammation is GC insensitive [28]. Inhaled corticosteroids
(ICS) are the mainstay of anti-inflammatory treatment for asthma,
often in combination with long-acting b2-agonists. The treatment
with inhaled corticosteroids for controlling allergic rhinitis and
asthma has proven the effectiveness in chronic persistent stages of
airway diseases [29] and is consistent with systemic and airway
inflammation common in all different stages of allergic disease
[30]. The treatment with a combination of ICS and LABA is
better than the use of higher doses of ICS alone [30] and is
appropriate to counteract the mechanism of IL-17A mediated
inflammation. We show here that the combined use of ICS and
LABA is efficient in interfering positively with the Th17-IL-17A
mediated inflammation in children, however their combined use
in children remains controversial [31]. To further support the
combined use of Budesonide and Formoterol we show that the two
drugs are able to control the cultured Th17 phenotype by reducing
Figure 7. Effect of 12 weeks treatment with inhaled Budesonide and Formoterol. Pediatric patients with MA/PR were treated with
Budesonide and Formoterol for 12 weeks and the effect was evaluated before and after the treatment on A) plasma IL-17A levels (pg/ml); B) CD4+ IL-
17A+T-cells (%); C) Ss IL-17A levels (pg/g sputum). Results are expressed as individual data points and the lateral bars represent median (25–75
percentiles). Statistical analysis was performed by Wilcoxon U-test. Significance was at p,0.05.
doi:10.1371/journal.pone.0058892.g007
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the levels of intracellular IL-17A and RORc(t), and conversely
increases the levels of intracellular Foxp3 in T-lymphocytes from
children with MA/PR, affecting the subtype CD4+IL-17A+ and
CD4+CD25+FoxP3+ T-cells. These findings suggest that ICS and
LABA might be able to control the Th17/RORc(t) pathway, and
can restore the Th17/Treg balance increasing the Treg in allergic
children. Furthermore, our findings support the concept that using
the drugs in combination the ICS are able to increase b2receptor
expression in the cells, increasing the antinflammatory activity of
LABA toward IL-17 activity.
Recent in vitro studies have demonstrated that IL-17A induces
epigenetic changes which in turn diminish the ability for GCs to
inhibit IL-8 production from human bronchial epithelial cells
16HBE [7]. Accordingly, the presence of bronchial inflammation
associated with IL-8 was observed in the Ss from children with
asthma, with higher levels in the airways of children with MA
despite the ICS treatment [32]. Therefore, our in vitro results
show that ICS and LABA might be able to improve the
pharmacological response to the GC in the regulation of
inflammatory events, generated by IL-17A present in the NW
and in the Ss from children with MA/PR, and associated with IL-
8 release from nasal and bronchial epithelial cell lines. Further-
more, we tested the effectiveness of ICS and LABA in a small
number of patients with MA/PR treated for twelve weeks with
inhaled Budesonide and Formoterol. Our finding clearly show that
the association of the two drugs is able to reduce the levels of IL-
17A in plasma and in the Ss, and to reduce the number of the
circulating CD4+IL17A+ T-cells. All together these findings
suggest that, although the combined use of ICS and LABA
remains controversial in allergic disease of children, the treatment
with ICS and LABA might be a useful tool for the management of
systemic and local inflammation in childhood allergic disease of
the airways. Further studies are necessary to better investigate the
effectiveness of ICS and LABA on additional inflammatory
pathways, including the levels of IL-8 produced within the
airways, in children with asthma and rhinitis.
In conclusion, we have demonstrated that Th17 cells producing
IL-17A are more frequently observed in allergic asthma and
rhinitis in children, showing a role in the systemic and local
inflammation, reinforcing the concept of the ‘‘united airway
disease’’. In this scenario, the understanding of the IL-17A biology
might be crucial in the development of novel therapeutic
approaches for the resolution of inflammation associated with
crosstalk between innate and adaptive immunity during the
allergic process of rhinitis and asthma, often insensitive to
glucocorticosteroids treatment. Our results suggest the potential
therapeutic approach with ICS and LABA to control systemic and
local inflammation generated by the Th17 immunity in children
with allergic airways diseases.
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